15.10.2014Spinomix Granted New US Patents for its MagPhase Core TechnologyYou are hereNewsSpinomix Granted New US Patents for its MagPhase Core Technology
Spinomix Granted New US Patents for its MagPhase Core Technology
Automated sample preparation platform based on magnetic beads and microfluidics
Robust and highly flexible automation brought to every laboratory bench
Offers new avenues in assay processing for life science research and diagnostics
Company in discussions with commercial partners and in process of raising new funds
Lausanne, Switzerland – October 15, 2014 – Spinomix SA a Swiss technology platform company providing innovative sample processing solutions to the life sciences sector, today announced the issuance of two US Patents number US 8,585,279 and US 8,870,446 relating to the manipulation and mixing of magnetic particles in microfluidics environments.
Spinomix's proprietary technology MagPhase™ has also been granted protection in China and Japan and is in its final granting stages in Europe. These highly strategic patents raise the company's MagPhase™ US granted patent portfolio to three patents; three others are still pending approval.
“This new patent grant is of great strategic importance for Spinomix since it confirms the originality of our method and its capability of leveraging the great applications possible with magnetic beads based assays and their easy automation using microfluidic based systems,” said Amar Rida, Founder and Chief Technology Officer of Spinomix. “Our company is continuously committed to innovation in order to provide the marketplace with novel solutions capable of shortening the path between sample collection and results analysis.”
Although magnetic beads technology has been around since the mid 1970s, the uniqueness of the company’s MagPhase™ technology is in the innovative way of homogenously handling these beads in connection with fluids handling in microfluidics based systems, thus enhancing bioassays efficiency and opening new fields for sample processing automation. The company’s goal with MagPhase™ is to bring affordable and flexible automation to every laboratory bench.
The technology is being developed for life science research as well as applications which are critical for treatment decisions such as circulation tumour nucleic acids for cancer diagnosis or cell isolation in regenerative medicine.
“Our vision is to expand our microfluidics cartridges to all of the currently available applications of magnetic beads such as protein purification, cell isolation and others. We are already applying our technology to nucleic acid purification, a market estimated to be well over one billion dollars,” said Spinomix Chief Executive Officer Nasri Nahas. “Spinomix is well on its way to becoming a sustainable business, supported by discussions with major market players to bring our products to market.”
BioAlps World Visibitlity Package 201918.03.2019A yearly international programme for our affiliated companies to increase their visibility.
BioAlps World Visibitlity Package 2019A yearly international programme for our affiliated companies to increase their visibility.
iOnctura SATherapeutics & Diagnostics
iOnctura, headquartered in Geneva, Switzerland, was founded in June 2017 as a spin out from Merck KGaA, funded by Merck Ventures. It is a late stage preclinical biotechnology company developing a pipeline of next generation, best-in-class molecules for the treatment of cancer and fibrosis.
Therapeutics & Diagnostics, Antibodies / Anti-infectives
Therapeutics & Diagnostics, Chemical Drug, small Molecules
Programs in oncology aim to harness both immune-mediated and direct anti-tumour activity to deliver superior clinical efficacy in monotherapy or combinations. By building on complementary mechanisms between cancer and fibrosis iOnctura further aims to address high unmet need in fibrotic disease.